文献速递胸部骨肌CT

早期成骨性改变预测非小细胞肺癌骨转移患者的化疗反应

Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases.
PubMed 文献 · Eur Radiol · 2018-04-12

研究纳入52例非小细胞肺癌骨转移患者,按CT特征分为成骨性改变组与无成骨性改变组,成骨性改变组3个月疾病控制率显著更高,1年无进展生存率74.9% vs 30.2%,早期成骨性改变可预测化疗反应。

要点

  • 化疗后中位2个月(范围1-3个月)出现成骨性改变,CT上可见骨病灶密度增高。
  • 成骨性改变组3个月疾病控制率显著高于无成骨性改变组(p<0.001)。
  • 成骨性改变组1年无进展生存率74.9%,无成骨性改变组30.2%。

核心结论

  • 早期成骨性改变可预测非小细胞肺癌骨转移患者的化疗反应。

研究设计与样本

  • 研究纳入2010年1月1日至2015年6月31日的52例非小细胞肺癌骨转移患者,依据CT特征分为成骨性改变组和无成骨性改变组。
  • 采用Kaplan-Meier曲线分析无进展生存期,并进行单因素和多因素Cox回归分析影响无进展生存期的因素。

关键影像表现/征象

  • 35/52例患者观察到成骨性改变,出现成骨性改变的中位时间为化疗后2个月(范围1-3个月)。

诊断标准与关键数值

  • 成骨性改变组3个月疾病控制率显著高于无成骨性改变组(p<0.001)。
  • 成骨性改变组1年无进展生存率74.9%,无成骨性改变组30.2%(p<0.001)。
  • 单因素Cox回归显示病理亚型(HR=4.419;95%CI=1.635-11.941,p=0.003)和成骨性改变(HR=0.199;95%CI=0.083-0.477,p<0.001)是PFS的显著预测因素。

临床应用与阅片要点

  • 化疗后随访CT时注意骨病灶是否出现成骨性改变,其出现时间中位为2个月。
  • 成骨性改变与更高的3个月疾病控制率和1年无进展生存率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To explore the relationship between osteosclerotic changes and chemotherapy response in non-small-cell lung cancer (NSCLC) patients with bone metastases (BM).

METHODS: Fifty-two NSCLC patients with BM were enrolled from 1 January 2010-31 June 2015 and divided into two groups based on their CT features: an osteosclerotic change (OC) group and a no-osteosclerotic change (NOC) group. The disease control rate (DCR) was evaluated, and progression-free survival (PFS) was analysed using Kaplan-Meier curves. Univariate and multivariate Cox regression analyses were performed to analyse the factors that could affect PFS.

RESULTS: Osteosclerotic changes were observed in 35/52 patients. The median interval when osteosclerotic changes occurred was 2 months (range 1-3 months) after chemotherapy. The OC group had a significantly higher 3-month DCR than the NOC group (p < 0.001). The OC group had a higher 1-year PFS rate than the NOC group (1-year PFS: 74.9% vs. 30.2%, p < 0.001). Univariate Cox regression analysis indicated that pathological subtype (HR = 4.419; 95% CI = 1.635-11.941, p = 0.003) and osteosclerotic changes (HR = 0.199; 95% CI = 0.083-0.477, p < 0.001) were significant predictors of PFS.

CONCLUSION: Early osteosclerotic changes predict chemotherapy response in NSCLC patients with BM.

KEY POINTS: • Osteosclerotic changes were prevalent CT features after chemotherapy in NSCLC patients. • Osteosclerotic changes were positively related to increased 3-month DCR. • Osteosclerotic changes were positively related to increased 1-year PFS rate.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rong D, Mao Y, Yang Q, et al. Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases. Eur Radiol. 2018. PMID: 29651766. doi:10.1007/s00330-017-5253-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。